Effect of Tirzepatide, a Dual GIP and GLP-1 Receptor Agonist, on Glycemic Control and Body Weight in Japanese Patients with T2DM

被引：5
|
作者：
Ohwaki, Kenji
Furihata, Kenichi
Mimura, Hanaka
Oura, Tomonori
Imaoka, Takeshi
机构：
来源：
DIABETES | 2019年 / 68卷
关键词：
D O I：
10.2337/db19-1024-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1024-P
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide for weight loss: a meta-analysis of randomized controlled trials
    de Mesquita, Yasmin Luz Lima
    Calvi, Izabela Pera
    Marques, Isabela Reis
    Cruz, Sara Almeida
    Padrao, Eduardo Messias Hirano
    Carvalho, Pedro Emanuel de Paula
    da Silva, Caroliny Hellen Azevedo
    Cardoso, Rhanderson
    Moura, Filipe Azevedo
    Rafalskiy, Vladimir Vitalievich
    INTERNATIONAL JOURNAL OF OBESITY, 2023, 47 (10) : 883 - 892
  • [32] Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP
    Wang, Lijing
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2022, 16 : 1547 - 1559
  • [33] Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis
    Karagiannis, Thomas
    Avgerinos, Ioannis
    Liakos, Aris
    Del Prato, Stefano
    Matthews, David R.
    Tsapas, Apostolos
    Bekiari, Eleni
    DIABETOLOGIA, 2022, 65 (08) : 1251 - 1261
  • [34] Insulin requirements after switching from GLP-1 receptor agonist to dual GIP/GLP-1 receptor agonist in patients with type 2 diabetes mellitus
    Lahey, Alexa M.
    Duprey, Karolyn
    Montague, Riley C.
    Schadler, Aric D.
    Naseman, Kristina W.
    PHARMACOTHERAPY, 2025,
  • [35] Tirzepatide, a dual GIP and GLP-1 receptor agonist, improves markers of beta cell function and insulin sensitivity in type 2 diabetes patients
    Thomas, M. K.
    Nikooienejad, A.
    Bray, R.
    Cui, X.
    Wilson, J.
    Duffin, K.
    Milicevic, Z.
    Haupt, A.
    Robins, D. A.
    DIABETOLOGIA, 2019, 62 : S354 - S354
  • [36] Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis
    Thomas Karagiannis
    Ioannis Avgerinos
    Aris Liakos
    Stefano Del Prato
    David R. Matthews
    Apostolos Tsapas
    Eleni Bekiari
    Diabetologia, 2022, 65 : 1251 - 1261
  • [37] PSYCHOMETRIC EVALUATION OF THE NV QUESTIONNAIRE IN PATIENTS WITH T2DM RECEIVING A GLP-1 AGONIST
    McLeod, L.
    Sikirica, M., V
    Qin, S.
    Joshi, A., V
    Sweeney, C. T.
    Blum, S., I
    VALUE IN HEALTH, 2017, 20 (05) : A175 - A175
  • [38] Gastrointestinal Adverse Effects of Dual GLP-1 and GIP Receptor Agonist Used for Weight Loss
    Wright, Joseph
    Russell, Joseph
    Tran, Jefferson
    Tran, Thomas
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S2970 - S2970
  • [39] The Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide Attenuates Colon Cancer Development by Regulating Glucose Metabolism
    Zhang, Yikai
    Xie, Yi
    Xia, Shenglong
    Ge, Xinnuo
    Li, Jiaying
    Liu, Fang
    Jia, Fan
    Wang, Shengyao
    Zhou, Qiao
    Gao, Menghan
    Fang, Weihuan
    Zheng, Chao
    ADVANCED SCIENCE, 2025,
  • [40] The Dual GIP and GLP-1 Receptor Agonist Tirzepatide Regulates Lipid and Carbohydrate Metabolism through GIPR in Adipose Tissue
    Samms, Ricardo Justin
    Christe, Michael E.
    Ruan, Xiaoping
    Moyers, Julie
    Regmi, Ajit
    Roell, William C.
    DIABETES, 2019, 68
12345